Clinical Trials Browser

Pancreatic Neoplasms

Pancreatic Neoplasms

Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Gallbladder Neoplasms, Cholangiocarcinoma

Pancreatic Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Esophageal Squamous Cell Carcinoma

Pancreatic Neoplasms

Colorectal Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Digestive System Neoplasms

Pancreatic Adenocarcinoma Metastatic

Carcinoma, Hepatocellular

Esophageal Neoplasms

Esophageal Neoplasms

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Colonic Neoplasms, Stomach Neoplasms

Digestive System Neoplasms, Neuroendocrine Tumors

Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Gastrointestinal Stromal Tumors

Carcinoma, Hepatocellular

Clinical Trials

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

SAIB

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

PAAG

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

TAS-102 and Anlotinib in ≥3 Lines mGC

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

ALTER-G-001

RCT-PAAG

FAITH

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

ALTER-C003

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Adjuvant Therapy With Anlotinib for HCC

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

ALTER-H-002

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

ALTER0802